Editors

The Problem with Gout Is That It’s Still Such a Problem
B.W. Coburn, T.R. Mikuls ........................................... 1453

A Comparison of CAROC and FRAX in Patients with Fragility Fracture
J.D. Adachi, A. Lau, A. Papaioannou ................................ 1456

Giant Cell Arteritis: Visual Loss Is Our Major Concern
M.A. Gonzalez-Gay, S. Castañeda, J. Llorca ......................... 1458

Review

Adapting Knowledge Translation Strategies for Rare Rheumatic Diseases
T. Cellucci, S. Lee, F. Webster ........................................ 1462

Articles

Telomere Length and Coronary Atherosclerosis in RA

Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with RA: An Observational Cohort Study
Y. Hattori, T. Kojima, A. Kaneko, et al ................................. 1475

MTX Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial

Differences in Clinical Features and Mortality between Childhood-onset and Adult-onset SLE: A Prospective Single-center Study
Y.B. Joo, S.Y. Park, S. Won, S.C. Bae ................................... 1490

Patients with SLE Have increased Risk of Short-term Adverse Events after Total Hip Arthroplasty

Risk of Serious Infection for Patients with SLE Starting Glucocorticoids with or without Antimalarials
L.J. Herrinton, L. Liu, R. Goldfien, M.A. Michaels, T.N. Tran ......................................................... 1503

Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician’s Global Assessment of Disease Severity in SSC
D. Harel, M. Hudson, A. Iliescu, M. Baron, Canadian Scleroderma Research Group, R. Steele .......................... 1510

Thermographic Abnormalities are Associated with Future Digital Ulcers and Death in Patients with SSC
M. Hughes, J. Wilkinson, T. Moore, et al .............................. 1519

Differential Expression Profiles of Long Noncoding RNA and mRNA of Osteogenically Differentiated Mesenchymal Stem Cells in Ankylosing Spondylitis
Z. Xie, J. Li, P. Wang, et al ............................................ 1523

Instrumented BASFI (iBASFI) Shows Promising Reliability and Validity in the Assessment of Activity Limitations in Axial Spondyloarthritis
T.W. Swinnen, M. Milosevic, S. Van Huffel, W. Dankaerts, R. Westhovens, K. de Vlam ........................................ 1532

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study
E. Lubrano, F. Massimo Perrotta, M. Manara, et al ............... 1541

Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients
A. Régent, S. Redeker, A. Deroux, et al, for the French Vasculitis Group, the Groupe Francais pour l’Etude de l’Arterite a Cellules Geantes, and the Club Rhumatismes et Inflammation ........................................ 1547

Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population
M. Englund, P.A. Merkel, G. Tomasson, M. Segelmark, A.J. Mohammad ......................................................... 1553

Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study
M. Saleh, C. Turesson, M. Englund, P.A. Merkel, A.J. Mohammad ......................................................... 1559

Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response
J. Bauhammer, N. Blank, R. Max, et al ................................. 1566

Free online via JRheum Full Release option

Contents continued on page xii